4BIO Capital β Full Portfolio
12 tracked investments Β· listed companies and verified rows first
Hornet Therapeutics is a biotech company developing treatments for Epstein-Barr Virus (EBV) driven diseases, with a lead IDO-1 inhibitor (HTX-201) aimed at preventing EBV-implicated conditions such as post-transplantation lymphoproliferative disease.
BiotechMedical Devices
Christoph Hess(Co-founder (Professor))
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission BiocapitalCancer FundFitz Gate VenturesModi VenturesPortal InnovationsTMC Venture Fund+1 more
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesM VenturesSofinnova PartnersBioqube Ventures
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)Amgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more
Hornet is a social networking and chat app for gay men and the broader queer community, offering messaging, a content feed, short videos, and discovery features.
ConsumerImpact & Social GoodMedia & EntertainmentSocial
Christof Wittig(Founder)inDamien BrenierinMitchell Geere
Co-investors500 GlobalMoai CapitalVentech China
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsFast Track InitiativeRemiges Ventures, Inc.DCI Partners Co. Ltd.
Trogenix develops precision genetic medicines for cancer treatment using proprietary Synthetic Super-Enhancers technology delivered via AAV vectors, targeting solid tumors with personalized in situ vaccinations.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Co-investorsACADEMY INVESTORLongeVCAIN VenturesIQ Capital
.jpeg){kind=logo}
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
BiotechDeep TechHealthtech
Co-investorsAIN VenturesCalculus Capital Ltd.IQ CapitalLongeVC
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)Origin CapitalUCB Ventures
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Cytospire TherapeuticsRay TherapeuticsRedpin Therapeutics
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.